{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:28:44Z","timestamp":1789972124445,"version":"4.0.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,11,21]],"date-time":"2014-11-21T00:00:00Z","timestamp":1416528000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Oral Invest"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1007\/s00784-014-1358-3","type":"journal-article","created":{"date-parts":[[2014,11,21]],"date-time":"2014-11-21T08:35:19Z","timestamp":1416558919000},"page":"1307-1318","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Zoledronate but not denosumab suppresses macrophagic differentiation of THP-1 cells. An aetiologic model of bisphosphonate-related osteonecrosis of the jaw (BRONJ)"],"prefix":"10.1007","volume":"19","author":[{"given":"Sebastian","family":"Hoefert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Sade","family":"Hoefert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Albert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelheid","family":"Munz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hinnak","family":"Northoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegmar","family":"Reinert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothea","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,11,21]]},"reference":[{"key":"1358_CR1","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","volume":"48","author":"R Baron","year":"2011","unstructured":"Baron R, Ferrari S, Russell RG (2011) Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48:677\u2013692","journal-title":"Bone"},{"key":"1358_CR2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10006-005-0624-6","volume":"9","author":"S Hoefert","year":"2005","unstructured":"Hoefert S, Eufinger H (2005) Osteonecrosis of the jaws as a possible adverse effect of the use of bisphosphonates. Mund Kiefer Gesichtschir 9:233\u2013238","journal-title":"Mund Kiefer Gesichtschir"},{"key":"1358_CR3","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.bcp.2006.09.031","volume":"73","author":"MF Moreau","year":"2007","unstructured":"Moreau MF, Guillet C, Massin P, Chevalier S, Gascan H, Basle MF et al (2007) Comparative effects of five bisphosphonates on apoptosis of macrophage cells in vitro. Biochem Pharmacol 73:718\u2013723","journal-title":"Biochem Pharmacol"},{"key":"1358_CR4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","volume":"49","author":"RG Russell","year":"2011","unstructured":"Russell RG (2011) Bisphosphonates: the first 40\u00a0years. Bone 49:2\u201319","journal-title":"Bone"},{"key":"1358_CR5","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","volume":"48","author":"A Lipton","year":"2012","unstructured":"Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA et al (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48:3082\u20133092","journal-title":"Eur J Cancer"},{"key":"1358_CR6","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrd3705","volume":"11","author":"DL Lacey","year":"2012","unstructured":"Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK et al (2012) Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov 11:401\u2013419","journal-title":"Nat Rev Drug Discov"},{"key":"1358_CR7","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132\u20135139","journal-title":"J Clin Oncol"},{"key":"1358_CR8","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J et al (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125\u20131132","journal-title":"J Clin Oncol"},{"key":"1358_CR9","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813\u2013822","journal-title":"Lancet"},{"issue":"5","key":"1358_CR10","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.joms.2009.01.009","volume":"67","author":"SL Ruggiero","year":"2009","unstructured":"Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B (2009) American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws\u20132009 update. J Oral Maxillofac Surg 67(5):2\u201312","journal-title":"J Oral Maxillofac Surg"},{"key":"1358_CR11","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","volume":"23","author":"F Saad","year":"2012","unstructured":"Saad F, Brown JE, Van PC, Ibrahim T, Stemmer SM, Stopeck AT et al (2012) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23:1341\u20131347","journal-title":"Ann Oncol"},{"key":"1358_CR12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2249.2005.02665.x","volume":"139","author":"RE Hewitt","year":"2005","unstructured":"Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK (2005) The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol 139:101\u2013111","journal-title":"Clin Exp Immunol"},{"key":"1358_CR13","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00198-010-1326-y","volume":"22","author":"S Ferrari-Lacraz","year":"2011","unstructured":"Ferrari-Lacraz S, Ferrari S (2011) Do RANKL inhibitors (denosumab) affect inflammation and immunity? Osteoporos Int 22:435\u2013446","journal-title":"Osteoporos Int"},{"key":"1358_CR14","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115\u20131117","journal-title":"J Oral Maxillofac Surg"},{"key":"1358_CR15","doi-asserted-by":"crossref","first-page":"981","DOI":"10.14219\/jada.archive.2012.0323","volume":"143","author":"P Diz","year":"2012","unstructured":"Diz P, Lopez-Cedrun JL, Arenaz J, Scully C (2012) Denosumab-related osteonecrosis of the jaw. J Am Dent Assoc 143:981\u2013984","journal-title":"J Am Dent Assoc"},{"key":"1358_CR16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cxom.2013.05.004","volume":"21","author":"SL Ruggiero","year":"2013","unstructured":"Ruggiero SL (2013) An office-based approach to the diagnosis and management of osteonecrosis. Atlas Oral Maxillofac Surg Clin North Am 21:167\u2013173","journal-title":"Atlas Oral Maxillofac Surg Clin North Am"},{"key":"1358_CR17","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.3109\/00016357.2013.765592","volume":"71","author":"D Carmagnola","year":"2013","unstructured":"Carmagnola D, Canciani E, Sozzi D, Biglioli F, Moneghini L, Dellavia C (2013) Histological findings on jaw osteonecrosis associated with bisphosphonates (BONJ) or with radiotherapy (ORN) in humans. Acta Odontol Scand 71:1410\u20131417","journal-title":"Acta Odontol Scand"},{"key":"1358_CR18","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.bone.2009.05.008","volume":"45","author":"G Favia","year":"2009","unstructured":"Favia G, Pilolli GP, Maiorano E (2009) Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy. Bone 45:406\u2013413","journal-title":"Bone"},{"key":"1358_CR19","doi-asserted-by":"crossref","first-page":"260","DOI":"10.4103\/1947-2714.110429","volume":"5","author":"V Kumar","year":"2013","unstructured":"Kumar V, Sinha RK (2013) Evolution and etiopathogenesis of bisphosphonates induced osteonecrosis of the jaw. N Am J Med Sci 5:260\u2013265","journal-title":"N Am J Med Sci"},{"key":"1358_CR20","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.oooo.2013.09.076","volume":"117","author":"AC Jones","year":"2014","unstructured":"Jones AC, Sedghizadeh PP (2014) Bisphosphonate-related osteonecrosis of the jaws is caused by dental procedures that violate oral epithelium; this is no longer a mysterious disease. Oral Surg Oral Med Oral Pathol Oral Radiol 117:392\u2013393","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"1358_CR21","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJM199903043400914","volume":"340","author":"V Kunzmann","year":"1999","unstructured":"Kunzmann V, Bauer E, Wilhelm M (1999) Gamma\/delta T-cell stimulation by pamidronate. N Engl J Med 340:737\u2013738","journal-title":"N Engl J Med"},{"key":"1358_CR22","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1359\/jbmr.2005.20.12.2274","volume":"20","author":"PJ Bekker","year":"2005","unstructured":"Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT et al (2005) A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. 2004. J Bone Miner Res 20:2275\u20132282","journal-title":"J Bone Miner Res"},{"key":"1358_CR23","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1601-6343.2009.01456.x","volume":"12","author":"DB Burr","year":"2009","unstructured":"Burr DB, Allen MR (2009) Mandibular necrosis in beagle dogs treated with bisphosphonates. Orthod Craniofac Res 12:221\u2013228","journal-title":"Orthod Craniofac Res"},{"key":"1358_CR24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1746-160X-6-11","volume":"6","author":"C Walter","year":"2010","unstructured":"Walter C, Al-Nawas B, Frickhofen N, Gamm H, Beck J, Reinsch L et al (2010) Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients. Head Face Med 6:11. doi: 10.1186\/1746-160X-6-11","journal-title":"Head Face Med"},{"key":"1358_CR25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00774-010-0162-7","volume":"28","author":"T Yoneda","year":"2010","unstructured":"Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S et al (2010) Bisphosphonate-related osteonecrosis of the jaw: position paper from the allied task force committee of Japanese society for bone and mineral research, Japan osteoporosis society, Japanese society of periodontology, Japanese society for oral and maxillofacial radiology, and Japanese society of oral and maxillofacial surgeons. J Bone Miner Metab 28:365\u2013383","journal-title":"J Bone Miner Metab"},{"key":"1358_CR26","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10147-013-0561-6","volume":"19","author":"WX Qi","year":"2014","unstructured":"Qi WX, Tang LN, He AN, Yao Y, Shen Z (2014) Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol 19:403\u2013410","journal-title":"Int J Clin Oncol"},{"key":"1358_CR27","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1093\/jnci\/djq516","volume":"103","author":"M Pazianas","year":"2011","unstructured":"Pazianas M (2011) Osteonecrosis of the jaw and the role of macrophages. J Natl Cancer Inst 103:232\u2013240","journal-title":"J Natl Cancer Inst"},{"key":"1358_CR28","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ijc.2910260208","volume":"26","author":"S Tsuchiya","year":"1980","unstructured":"Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K (1980) Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 26:171\u2013176","journal-title":"Int J Cancer"},{"key":"1358_CR29","doi-asserted-by":"crossref","first-page":"e8668","DOI":"10.1371\/journal.pone.0008668","volume":"1","author":"M Daigneault","year":"2010","unstructured":"Daigneault M, Preston JA, Marriott HM, Whyte MK, Dockrell DH (2010) The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages. PLoS ONE 1:e8668","journal-title":"PLoS ONE"},{"key":"1358_CR30","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ejpb.2009.07.004","volume":"73","author":"VE Plattner","year":"2009","unstructured":"Plattner VE, Ratzinger G, Engleder ET, Gallauner S, Gabor F, Wirth M (2009) Alteration of the glycosylation pattern of monocytic THP-1 cells upon differentiation and its impact on lectin-mediated drug delivery. Eur J Pharm Biopharm 73:324\u2013330","journal-title":"Eur J Pharm Biopharm"},{"key":"1358_CR31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.dental.2009.08.007","volume":"26","author":"E Urcan","year":"2010","unstructured":"Urcan E, Haertel U, Styllou M, Hickel R, Scherthan H, Reichl FX (2010) Real-time xCELLigence impedance analysis of the cytotoxicity of dental composite components on human gingival fibroblasts. Dent Mater 26:51\u201358","journal-title":"Dent Mater"},{"key":"1358_CR32","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/jbmr.1613","volume":"27","author":"GA Block","year":"2012","unstructured":"Block GA, Bone HG, Fang L, Lee E, Padhi D (2012) A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 27:1471\u20131479","journal-title":"J Bone Miner Res"},{"key":"1358_CR33","author":"S Hoefert","year":"2014","unstructured":"Hoefert S, Schmitz I, Weichert F, Gaspar M, Eufinger H (2014) Macrophages and bisphosphonate-related osteonecrosis of the jaw (BRONJ): evidence of local immunosuppression of macrophages in contrast to other infectious jaw diseases. Clin Oral Investig. doi: 10.1007\/s00784-014-1273-7","journal-title":"Clin Oral Investig"},{"key":"1358_CR34","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1126\/science.1178331","volume":"327","author":"F Geissmann","year":"2010","unstructured":"Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K (2010) Development of monocytes, macrophages, and dendritic cells. Science 327:656\u2013661","journal-title":"Science"},{"key":"1358_CR35","unstructured":"Jeganathan S, Fiorino C, Naik U, Sun HS, Harrison RE (2014) Modulation of osteoclastogenesis with macrophage M1- and M2-inducing stimuli. PLoS ONE 8:e104498. doi: 10.1371"},{"key":"1358_CR36","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/jbmr.1543","volume":"27","author":"AJ Roelofs","year":"2012","unstructured":"Roelofs AJ, Stewart CA, Sun S, Blazewska KM, Kashemirov BA, McKenna CE et al (2012) Influence of bone affinity on the skeletal distribution of fluorescently labeled bisphosphonates in vivo. J Bone Miner Res 27:835\u2013847","journal-title":"J Bone Miner Res"},{"key":"1358_CR37","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1002\/jbmr.5650111015","volume":"11","author":"MJ Rogers","year":"1996","unstructured":"Rogers MJ, Chilton KM, Coxon FP, Lawry J, Smith MO, Suri S et al (1996) Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism. J Bone Miner Res 11:1482\u20131491","journal-title":"J Bone Miner Res"},{"key":"1358_CR38","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1476-5381.2011.01592.x","volume":"165","author":"JW Kuiper","year":"2012","unstructured":"Kuiper JW, Forster C, Sun C, Peel S, Glogauer M (2012) Zoledronate and pamidronate depress neutrophil functions and survival in mice. Br J Pharmacol 165:532\u2013539","journal-title":"Br J Pharmacol"},{"key":"1358_CR39","author":"N Hagelauer","year":"2014","unstructured":"Hagelauer N, Pabst AM, Ziebart T, Ulbrich H, Walter C (2014) In vitro effects of bisphosphonates on chemotaxis, phagocytosis, and oxidative burst of neutrophil granulocytes. Clin Oral Investig. doi: 10.1007\/s00784-014-1219-0","journal-title":"Clin Oral Investig"},{"key":"1358_CR40","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1258\/ebm.2011.011168","volume":"236","author":"G Orsini","year":"2011","unstructured":"Orsini G, Failli A, Legitimo A, Adinolfi B, Romanini A, Consolini R (2011) Zoledronic acid modulates maturation of human monocyte-derived dendritic cells. Exp Biol Med (Maywood) 236:1420\u20131426","journal-title":"Exp Biol Med (Maywood)"},{"key":"1358_CR41","doi-asserted-by":"crossref","unstructured":"Cheng ML, Fong L (2014) Effects of RANKL-Targeted Therapy in Immunity and Cancer. Front Oncol 329. doi: 10.3389\/fonc.2013.00329","DOI":"10.3389\/fonc.2013.00329"},{"key":"1358_CR42","doi-asserted-by":"crossref","first-page":"30202","DOI":"10.1074\/jbc.M403968200","volume":"279","author":"D Seshasayee","year":"2004","unstructured":"Seshasayee D, Wang H, Lee WP, Gribling P, Ross J, van BN et al (2004) A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response. J Biol Chem 279:30202\u201330209","journal-title":"J Biol Chem"}],"container-title":["Clinical Oral Investigations"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00784-014-1358-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00784-014-1358-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00784-014-1358-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T02:34:36Z","timestamp":1559097276000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00784-014-1358-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,21]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["1358"],"URL":"https:\/\/doi.org\/10.1007\/s00784-014-1358-3","relation":{},"ISSN":["1432-6981","1436-3771"],"issn-type":[{"value":"1432-6981","type":"print"},{"value":"1436-3771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,21]]}}}